INTEGRA LIFESCIENCES HOLDINGS CORP
IARTDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How IART's past catalysts played out
Picosulfate sodium, magnesium oxide, citric acid
Bowel Preparation Before Colonoscopy
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Bowel Preparation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Picosulfate sodium, magnesium oxide, citric acid | Phase 3 | Bowel Preparation Before Colonoscopy | - | - |
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) | Phase 3 | Bowel Preparation | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in INTEGRA LIFESCIENCES HOLDINGS CORP's drug pipeline?→
CatalystAlert tracks 2 drug candidates in INTEGRA LIFESCIENCES HOLDINGS CORP's (IART) pipeline across Phase 3. Its lead program is Picosulfate sodium, magnesium oxide, citric acid (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INTEGRA LIFESCIENCES HOLDINGS CORP's next FDA catalyst?→
INTEGRA LIFESCIENCES HOLDINGS CORP's (IART) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IART biotech catalysts?→
Add IART to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INTEGRA LIFESCIENCES HOLDINGS CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.